Multiple Sclerosis (MS) is a major public health problem in Turkey with high cost implications. The objective of this study is to analyze the economic burden of illness for MS in Turkey, both from the payer's and society's perspective.
OBJECTIVES
Multiple Sclerosis (MS) is a major public health problem in Turkey with high cost implications. The objective of this study is to analyze the economic burden of illness for MS in Turkey, both from the payer's and society's perspective.
METHODS
The direct costs including diagnosis, treatment of MS attacks and symptoms, for RRMS, PPMS, SPMS are found to be 705.745.333 TRY (~115,6 mEUR) in total for the payer.
Medicines make only 61% of this direct burden of illness in MS. The indirect costs and economic losses caused by loss of productivity due to MS, are consisting of factors such as absenteeism, early retirement, early death, and cost of caregivers, which is a service required by most MS patients, and indirect costs sum up to 1.879.454.246 TRY (~307, 8 mEUR) for the society.
RESULTS
To be able to perform this study, total cost of MS was calculated by estimating direct and indirect costs. Direct costs estimations were performed in two phases. In the first phase, a Delphi Group, which consisted of 9 neurologists, was gathered to identify the direct costs of medicines, physician admissions, physiotherapy and diagnostic test requirements related with the disease. In the second phase of direct costs estimation, informations collected from Delphi Group, MS prevelance in Turkey data and Health Implementation Notification (SUT) price lists were utilized. For the indirect costs estimation, human capital approach has been preferred and Turkish Statistical Institute (TurkStat) was chosen as source for labor statatistics and and population/age distribution data.
CONCLUSION
In this study, the direct costs from payer's (SGK) perspective and the indirect costs from society's perspective are presented. To be able to perform more reliable indirect cost calculation, indirect cost data should be collected directly from MS patients. As this study indicates, MS disease and its treatment cause negative outcomes both on public health and economy. However, new innovative medicines for MS treatment are expected to reduce the negative effects of MS with increased cure rates and reduced relapce. Direct costs, including diagnosis, treatment of attacks and symptoms, RRMS, PPMS and SPMS, were found to be as follow;
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